{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:58:26Z","timestamp":1793642306527,"version":"4.5.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T00:00:00Z","timestamp":1589241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T00:00:00Z","timestamp":1589241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s12325-020-01365-3","type":"journal-article","created":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T16:25:07Z","timestamp":1589300707000},"page":"3019-3030","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Consensus Recommendations for Management and Counseling of Adverse Events Associated With Lorlatinib: A Guide for Healthcare Practitioners"],"prefix":"10.1007","volume":"37","author":[{"given":"Mollie","family":"Reed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee-Lauren S.","family":"Rosales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc D.","family":"Chioda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geeta","family":"Devgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Kettle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,12]]},"reference":[{"issue":"22","key":"1365_CR1","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1200\/JCO.2016.71.5904","volume":"35","author":"DW Kim","year":"2017","unstructured":"Kim DW, Tiseo M, Ahn MJ, et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial. J Clin Oncol. 2017;35(22):2490\u20138.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1365_CR2","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","volume":"377","author":"S Peters","year":"2017","unstructured":"Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377(9):829\u201338.","journal-title":"N Engl J Med"},{"issue":"23","key":"1365_CR3","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","volume":"371","author":"BJ Solomon","year":"2014","unstructured":"Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167\u201377.","journal-title":"N Engl J Med"},{"issue":"10072","key":"1365_CR4","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","volume":"389","author":"JC Soria","year":"2017","unstructured":"Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017;389(10072):917\u201329.","journal-title":"Lancet"},{"issue":"10","key":"1365_CR5","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","volume":"6","author":"JF Gainor","year":"2016","unstructured":"Gainor JF, Dardaei L, Yoda S, et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov. 2016;6(10):1118\u201333.","journal-title":"Cancer Discov"},{"issue":"120","key":"1365_CR6","doi-asserted-by":"publisher","first-page":"120ra117","DOI":"10.1126\/scitranslmed.3003316","volume":"4","author":"R Katayama","year":"2012","unstructured":"Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med. 2012;4(120):120ra117.","journal-title":"Sci Transl Med"},{"issue":"2","key":"1365_CR7","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jtho.2019.10.014","volume":"15","author":"JJ Lin","year":"2020","unstructured":"Lin JJ, Schoenfeld AJ, Zhu VW, et al. Efficacy of platinum\/pemetrexed combination chemotherapy in ALK-positive NSCLC refractory to second-generation ALK inhibitors. J Thorac Oncol. 2020;15(2):258\u201365.","journal-title":"J Thorac Oncol"},{"issue":"11","key":"1365_CR8","doi-asserted-by":"publisher","first-page":"4720","DOI":"10.1021\/jm500261q","volume":"57","author":"TW Johnson","year":"2014","unstructured":"Johnson TW, Richardson PF, Bailey S, et al. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(m etheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J Med Chem. 2014;57(11):4720\u201344.","journal-title":"J Med Chem"},{"issue":"1","key":"1365_CR9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ccell.2015.05.010","volume":"28","author":"HY Zou","year":"2015","unstructured":"Zou HY, Friboulet L, Kodack DP, et al. PF-06463922, an ALK\/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models. Cancer Cell. 2015;28(1):70\u201381.","journal-title":"Cancer Cell"},{"issue":"11","key":"1365_CR10","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1073\/pnas.1420785112","volume":"112","author":"HY Zou","year":"2015","unstructured":"Zou HY, Li Q, Engstrom LD, et al. PF-06463922 is a potent and selective next-generation ROS1\/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. Proc Natl Acad Sci U S A. 2015;112(11):3493\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"1365_CR11","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","volume":"18","author":"AT Shaw","year":"2017","unstructured":"Shaw AT, Felip E, Bauer TM, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol. 2017;18(12):1590\u20139.","journal-title":"Lancet Oncol"},{"issue":"12","key":"1365_CR12","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","volume":"19","author":"BJ Solomon","year":"2018","unstructured":"Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19(12):1654\u201367.","journal-title":"Lancet Oncol"},{"key":"1365_CR13","unstructured":"Pfizer (2018). LORBRENA\u00ae (lorlatinib) tablets, for oral use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210868s000lbl.pdf. Accessed 7 Feb 2019."},{"issue":"12","key":"1365_CR14","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/S1470-2045(19)30655-2","volume":"20","author":"AT Shaw","year":"2019","unstructured":"Shaw AT, Solomon BJ, Chiari R, et al. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1\u20132 trial. Lancet Oncol. 2019;20(12):1691\u2013701.","journal-title":"Lancet Oncol"},{"issue":"8","key":"1365_CR15","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1634\/theoncologist.2018-0380","volume":"24","author":"TM Bauer","year":"2019","unstructured":"Bauer TM, Felip E, Solomon BJ, et al. Clinical management of adverse events associated with lorlatinib. Oncologist. 2019;24(8):1103\u201310.","journal-title":"Oncologist"},{"issue":"6","key":"1365_CR16","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","volume":"80","author":"PJ Neuvonen","year":"2006","unstructured":"Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80(6):565\u201381.","journal-title":"Clin Pharmacol Ther"},{"key":"1365_CR17","unstructured":"American Heart Association. 2018. How much sodium should I eat per day? https:\/\/www.heart.org\/en\/healthy-living\/healthy-eating\/eat-smart\/sodium\/how-much-sodium-should-i-eat-per-day. Accessed 17 Mar 2019."},{"issue":"3","key":"1365_CR18","doi-asserted-by":"publisher","first-page":"E111","DOI":"10.1188\/17.ONF.E111-E123","volume":"44","author":"H Haryani","year":"2017","unstructured":"Haryani H, Fetzer SJ, Wu CL, Hsu YY. Chemotherapy-induced peripheral neuropathy assessment tools: a systematic review. Oncol Nurs Forum. 2017;44(3):E111\u2013E23.","journal-title":"Oncol Nurs Forum"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01365-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-020-01365-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01365-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T23:36:28Z","timestamp":1620776188000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-020-01365-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,12]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["1365"],"URL":"https:\/\/doi.org\/10.1007\/s12325-020-01365-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,12]]},"assertion":[{"value":"30 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}